(firstQuint)Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis.

 The purpose of this multicenter, open-label study is to evaluate the safety, tolerability, and pharmacokinetics of RVT-501 0.

5% topical ointment administered twice daily (BID) for 4 weeks in pediatric patients age 2-11 years of age with extensive atopic dermatitis.

 The efficacy of RVT-501 will also be evaluated as a secondary objective in these patients.

 The study will consist of three phases: Screening (up to 30 days), Treatment Phase (28 days), and Follow-up (7-10 days).

.

 Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis@highlight

This is a multicenter, open-label Phase 1b study in pediatric patients age 2-11 years old with extensive atopic dermatitis.

